Nabriva Therapeutics plc Operating Lease, Expense
Nabriva Therapeutics plc reported Operating Lease, Expense of $1.40 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2021-03-11
- Nabriva Therapeutics plc operating lease, expense for the quarter ending 2020-12-31 was $400.00K, a 0.00% change year-over-year.
- Nabriva Therapeutics plc operating lease, expense for the quarter ending 2020-09-30 was $200.00K, a 50.00% decline year-over-year.
- Nabriva Therapeutics plc operating lease, expense for the quarter ending 2020-06-30 was $400.00K, a 0.00% change year-over-year.
- Nabriva Therapeutics plc operating lease, expense for the quarter ending 2020-03-31 was $400.00K, a 14.94% increase year-over-year.
- Nabriva Therapeutics plc operating lease, expense for fiscal 2020 was $1.40M, a 6.67% decline from fiscal 2019.
- Nabriva Therapeutics plc operating lease, expense for fiscal 2019 was $1.50M, a 7.14% increase from fiscal 2018.
- Nabriva Therapeutics plc operating lease, expense for fiscal 2018 was $1.40M, a 7.69% increase from fiscal 2017.
- Nabriva Therapeutics plc operating lease, expense for fiscal 2017 was $1.30M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2020-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $600.00K derived: sum of 2 quarters · filed 2021-03-11 | $1.00M derived: sum of 3 quarters · filed 2021-03-11 | $1.40M 10-K · filed 2021-03-11 |
| 2020-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $600.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.00M 10-Q · filed 2020-11-05 | $1.40M derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $800.00K 10-Q · filed 2020-08-06 | $1.20M derived: sum of 3 quarters · filed 2021-03-11 | $1.60M derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-03-31 | $400.00K 10-Q · filed 2020-05-11 | $800.00K derived: sum of 2 quarters · filed 2021-03-11 | $1.20M derived: sum of 3 quarters · filed 2021-03-11 | $1.60M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $800.00K derived: sum of 2 quarters · filed 2021-03-11 | $1.20M derived: sum of 3 quarters · filed 2021-03-11 | $1.50M 10-K · filed 2021-03-11 |
| 2019-09-30 | $400.00K 10-Q · filed 2019-11-12 | $800.00K derived: sum of 2 quarters · filed 2019-11-12 | $1.10M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $400.00K 10-Q · filed 2019-08-08 | $700.00K 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $348.00K 10-Q · filed 2019-05-10 | |||
| 2018-12-31 | $1.40M 10-K · filed 2021-03-11 | |||
| 2017-12-31 | $1.30M 10-K · filed 2020-03-12 |